Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). 

 

The Company has generated clinical proof of concept data in two important itch conditions: uremic pruritus and prurigo nodularis.

News
Trevi Therapeutics Hires Dr. Helena Brett-Smith as Chief Development Officer
10/12/2017
Highly experienced clinical drug developer to oversee R&D functions and Companys Phase 3 development program
Trevi Therapeutics Raises $50 Million Series C Financing Led by New Enterprise Associates
7/20/2017
Company continuing the development of Nalbuphine ER in chronic pruritus conditions
Trevi Therapeutics Names Michael Heffernan to its Board of Directors
3/7/2017
Senior pharma executive brings clinical development and commercial background as the Company moves into Phase 3 trials for Nalbuphine ER in chronic pruritus conditions